Childhood Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
β-arrestin1-mediated acetylation of Gli1 regulates Hedgehog/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cells.
|
28716052 |
2017 |
Childhood Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we use mouse and human medulloblastoma stem-like cells belonging to the Sonic Hedgehog subgroup (SHH MB-SLCs) and demonstrate that genetic suppression of EZH2 reduces the level of its histone mark H3K27me3 and lowers proliferation and self-renewal.
|
28978137 |
2017 |
Childhood Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this work, we provide evidence that 5-10 seconds of sampling from <i>ex vivo</i> MB tissue with PIRL-MS can allow robust tumour subgroup classification, and have identified several biomarker ions responsible for the statistical discrimination of MB Group 3 and the SHH subgroup.
|
28989676 |
2017 |
Childhood Medulloblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Medulloblastoma (MB) is a malignant childhood brain tumor which at molecular level is classified into at least four major subtypes: WNT, SHH, group C and group D differing in response to treatment.
|
29039487 |
2017 |
Childhood Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patched1 heterozygous (Ptch1 <sup>+/-</sup>) mice, carrying a germ-line heterozygous inactivating mutation in the Ptch1 gene, the Shh receptor and negative regulator of the pathway, are uniquely susceptible to MB development after radiation damage in neonatal cerebellum.
|
29079783 |
2017 |
Childhood Medulloblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Medulloblastoma (MB), the most common malignant childhood brain tumor, encompasses a collection of four clinically and molecularly distinct tumor subgroups, i.e.WNT, SHH, Group 3 and Group 4.
|
29108280 |
2017 |
Childhood Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have implemented several biochemical experiments using human MB tumor microarray (TMA) and pediatric MB cell lines, derived from high-risk SHH-TP53-mutated and MYC-amplified Non-WNT/SHH tumors.
|
29280516 |
2018 |
Childhood Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biomarkers were identified applying stringent selection filters and Linear Discriminant Analysis (LDA) method, and validated using DNA methylation microarray data, bisulfite pyrosequencing, and direct-bisulfite sequencing.<b>Results:</b> Using a LDA-based approach, we developed and validated a prediction method (<sup>Epi</sup>WNT-SHH classifier) based on six epigenetic biomarkers that allowed for rapid classification of medulloblastoma into the clinically relevant subgroups WNT, SHH, and non-WNT/non-SHH with excellent concordance (>99%) with current gold-standard methods, DNA methylation microarray, and gene signature profiling analysis.
|
29351917 |
2018 |
Childhood Medulloblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Indeed, our results delineate anti-neoplastic activity of Axitinib in medulloblastoma cell lines modelling the most aggressive c-myc-amplified Non-WNT/Non-SHH and SHH-TP53-mutated tumours.
|
29377550 |
2018 |
Childhood Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Opposing Effects of CREBBP Mutations Govern the Phenotype of Rubinstein-Taybi Syndrome and Adult SHH Medulloblastoma.
|
29551561 |
2018 |
Childhood Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Medulloblastoma (MB) is an embryonal tumour that originates from genetic deregulation of cerebellar developmental pathways and is classified into 4 molecular subgroups: SHH, WNT, group 3, and group 4.
|
29582271 |
2018 |
Childhood Medulloblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A Kaplan-Meier survival curve and multivariate Cox regression demonstrated that high M1 expressers showed worse overall survival (OS) and progression-free survival (PFS) than low M1 expressers in SHH MB, with relative risk (RR) values of 11.918 and 6.022, respectively.
|
29739450 |
2018 |
Childhood Medulloblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Targeting of oncogene-driven replicative stress as therapeutic option for high-risk medullobastoma was assessed using a panel of medulloblastoma cells differing in their c-Myc expression [i.e. group SHH (c-Myc low) vs. group 3 (c-Myc high)].
|
29753759 |
2018 |
Childhood Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MB tumors belonging to SHH molecular subgroup, with TP53<sup>MUT</sup>, would be the ones that present high risk in relation to VA use during the treatment, while TP53<sup>WT</sup> MBs can benefit from VA therapy, both SHH and groups 3 and 4.
|
29785653 |
2018 |
Childhood Medulloblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The parallel increase of c-Met and MAP4K4 expression in SHH MB could predict an increased potential of these tumors to infiltrate brain tissue and cause metastatic disease.
|
29796184 |
2018 |
Childhood Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study demonstrates the clinical utility of CD271 as both a diagnostic and prognostic tool for SHH medulloblastoma tumors and reveals a novel role for MEK inhibitors in targeting CD271<sup>+</sup> SHH medulloblastoma cells.<b>Significance:</b> This study identifies CD271 as a specific and novel biomarker of SHH-type medulloblastoma and that targeting CD271<sup>+</sup> cells through MEK inhibition represents a novel therapeutic strategy for the treatment of SHH medulloblastoma.<i></i>.
|
29930101 |
2018 |
Childhood Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunophenotypic characterization and methylation profiling suggested a medulloblastoma with SHH activation.
|
29971034 |
2018 |
Childhood Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study provides novel candidates whose functional role should be further investigated in SHH MB.
|
30096798 |
2018 |
Childhood Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic biomarkers and models identified were validated in an independent, demographically matched cohort (n=70) of medulloblastoma patients with non-WNT/non-SHH standard-risk disease treated with conventional therapies (maximal surgical resection followed by adjuvant craniospinal irradiation [all patients] and chemotherapy [65 of 70 patients], at UK Children's Cancer and Leukaemia Group and European Society for Paediatric Oncology (SIOPE) associated treatment centres between 1990 and 2014.
|
30392813 |
2018 |
Childhood Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Differential Expression of Mitochondrial Biogenesis Markers in Mouse and Human SHH-Subtype Medulloblastoma.
|
30841515 |
2019 |
Childhood Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein we report two adolescent patients with Group 4 and SHH medulloblastoma, where vinblastine successfully replaced vincristine with resolution of their peripheral neuropathy.
|
30848061 |
2019 |
Childhood Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of LDHA significantly reduced growth of both mouse and human <i>MYC</i>-driven tumors but had little effect on normal cerebellar cells or SHH-associated medulloblastoma.
|
30862721 |
2019 |
Childhood Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Medulloblastoma (MB) is a pediatric malignant brain tumor composed of four different subgroups (WNT, SHH, Group 3, Group 4), each of which are a unique biological entity with distinct clinico-pathological, molecular, and prognostic characteristics.
|
30890619 |
2019 |
Childhood Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Medulloblastoma (MB) is the most frequent malignant brain tumor in children and it is subgrouped into 4 entities (SHH, WNT, Group 3, and Group 4).
|
31073205 |
2019 |
Childhood Medulloblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent molecular analyses of pediatric and adult MB have classified these tumors into at least four individual molecular subgroups (SHH, WNT, group 3, and group 4) with distinct demographics, histology, and prognosis.
|
31236711 |
2019 |